Osteoporosis Medications Compared: Bisphosphonates vs. Denosumab

Osteoporosis Medications at a Glance

The fracture-risk-reduction figures above come from each drug's pivotal randomized controlled trial (FIT for alendronate, HORIZON for zoledronic acid, FREEDOM for denosumab, the Neer et al. teriparatide trial, and FRAME for romosozumab) and are not directly comparable across trials, since each enrolled a different baseline-risk population — they indicate relative strength within each drug's own study, not a head-to-head ranking.

Antiresorptive vs. Anabolic: What the Split Actually Means

Bone is never static tissue. Osteoclasts continuously remove old or damaged bone while osteoblasts lay down new bone to replace it — a cycle called remodeling. Osteoporosis develops when removal consistently outpaces formation, most commonly because declining estrogen after menopause removes a key brake on osteoclast activity.

Antiresorptive drugs — bisphosphonates and denosumab — work by slowing osteoclast activity. Bisphosphonates bind to bone mineral and get taken up by osteoclasts during resorption, where they interfere with the cell's ability to function. Denosumab works differently: it's a monoclonal antibody that binds RANKL, a signaling protein osteoclasts need to form and survive, so fewer osteoclasts are generated in the first place.

Anabolic drugs — teriparatide and romosozumab — push in the opposite direction: they stimulate osteoblasts to build new bone faster than the body would on its own. Teriparatide is a fragment of parathyroid hormone that, given as a daily pulse rather than the body's normal continuous low level, paradoxically favors bone formation over resorption. Romosozumab blocks sclerostin, a protein that normally restrains osteoblast activity, unleashing a faster bone-building response — while also modestly reducing resorption, making it the only drug on this page with a true dual mechanism.

Choosing by Fracture-Risk Severity

Endocrine Society and Endocrine Society-aligned specialty guidelines generally match drug class to FRAX 10-year fracture probability and T-score severity, not personal preference alone:

• Moderate risk (T-score -2.5 to -3.0, no prior fragility fracture): oral bisphosphonates (alendronate or risedronate) are typically first-line — lowest cost, decades of safety data, and adequate fracture-risk reduction for this risk band.
• High risk (T-score below -3.0, or a prior fragility fracture): denosumab or zoledronic acid are reasonable steps up, particularly when oral pill adherence is a concern or GI tolerance is poor.
• Very high risk (a recent vertebral or hip fragility fracture, multiple fractures, or a T-score below -3.5 with additional risk factors): anabolic therapy first — teriparatide or romosozumab — is increasingly favored, since building new bone quickly matters most when the near-term refracture risk is highest. Anabolic treatment is always followed by an antiresorptive to preserve the gains, since bone density typically declines again once the anabolic course ends.

Spine vs. Hip: Does the Fracture Site Change the Choice?

All five options reduce both vertebral and hip fracture risk, but the relative strength differs by drug, which matters when one site is the dominant concern. Romosozumab and teriparatide show their largest relative benefit at the spine (73% and 65-70% vertebral fracture reduction respectively) — consistent with trabecular bone, which makes up most of the vertebral body, responding faster to anabolic stimulation than the denser cortical bone of the hip. Zoledronic acid and denosumab show strong reduction at both sites, with zoledronic acid's HORIZON trial reporting a notably high 70% vertebral fracture reduction alongside a 41% hip fracture reduction. For a patient whose imaging shows existing vertebral compression fractures — the single strongest predictor of a future vertebral fracture — a spine-favoring option is often prioritized; for a patient with a parent's hip fracture history and low femoral-neck T-score, hip-focused evidence carries more weight in the discussion.

Kidney Function and Dental Work: Two Practical Decision Points

Kidney function. Bisphosphonates are cleared by the kidneys and are generally avoided or dose-reduced when eGFR falls below about 30-35 mL/min/1.73m², depending on the specific drug and guideline. Denosumab is not renally cleared and is often preferred in patients with reduced kidney function — though it carries its own risk of significant hypocalcemia in advanced chronic kidney disease, so calcium levels need close monitoring in that setting specifically.

Dental work. Osteonecrosis of the jaw is a rare but serious risk with both bisphosphonates and denosumab, occurring far more often with the high-dose IV formulations used in cancer treatment than with the doses used for osteoporosis (roughly 1 in 10,000 to 1 in 100,000 patient-years at osteoporosis doses). Guidelines generally recommend completing any planned invasive dental procedures, such as extractions or implants, before starting either drug class when practical, and coordinating with a dentist before any future invasive work once treatment has started.

Stopping denosumab specifically carries its own risk that the other drugs don't share: discontinuing denosumab causes a rebound surge in bone resorption, and case reports document multiple vertebral fractures occurring in the months after a missed or stopped dose. Anyone starting denosumab should have a clear plan with their prescriber for transitioning to a bisphosphonate if denosumab is ever discontinued, rather than simply stopping.

Side Effects Compared

Verdict: Which Osteoporosis Medication Is Right for You

There is no single "best" osteoporosis medication — the right choice is the one matched to your specific fracture risk, kidney function, and tolerance for the dosing schedule, decided with your prescriber using your DEXA T-score, FRAX score, and fracture history. As a starting framework: oral bisphosphonates remain the reasonable first step for moderate risk and normal kidney function; zoledronic acid or denosumab step up for higher risk, adherence concerns, or reduced kidney function; and teriparatide or romosozumab are reserved for very high, near-term fracture risk, always followed by an antiresorptive to lock in the gains. Our full osteoporosis diagnosis and treatment guide covers the DEXA and FRAX scoring that determines which risk band you fall into before this comparison becomes relevant.

What Makes a Good Bone-Support Supplement

Get calcium from food first; if you supplement, calcium citrate absorbs better than carbonate and is gentler without a meal. Keep total calcium (food + pills) around 1,000–1,200 mg/day — more doesn't help bone. Pair it with vitamin D3 and K2, which help calcium reach bone, and split doses to ~500 mg for better absorption.

Healtionist 2 Packs 2000mg Calcium Citrate with Vitamin D3 K2 Supplements Gummies for Women & Men, Magnesium, Zinc, High Absorption, Bone, Muscle & Immune Support, 120 Counts Peach Flavor Gummies

Healtionist

View on Amazon →

4-in-1 Calcium 1200 mg with Vitamin D3 K2 - Extra Strength Calcium Supplements for Women & Men with D3 K2 Vitamin 5000 IU - Everyday Vitality Supplement - Vegan-Friendly, Gluten-Free, Non-GMO (120ct)

PrimeMD

View on Amazon →